Sakiko Otani

858 total citations
45 papers, 613 citations indexed

About

Sakiko Otani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Sakiko Otani has authored 45 papers receiving a total of 613 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 33 papers in Pulmonary and Respiratory Medicine and 8 papers in Epidemiology. Recurrent topics in Sakiko Otani's work include Lung Cancer Treatments and Mutations (29 papers), Lung Cancer Research Studies (20 papers) and Colorectal Cancer Treatments and Studies (12 papers). Sakiko Otani is often cited by papers focused on Lung Cancer Treatments and Mutations (29 papers), Lung Cancer Research Studies (20 papers) and Colorectal Cancer Treatments and Studies (12 papers). Sakiko Otani collaborates with scholars based in Japan and United States. Sakiko Otani's co-authors include Satoshi Igawa, Jiichiro Sasaki, Noriyuki Masuda, Tomoya Fukui, Masato Katagiri, Masaru Kubota, Ken Katono, Hisashi Mitsufuji, Yasuhiro Hiyoshi and Akira Takakura and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Sakiko Otani

42 papers receiving 603 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sakiko Otani Japan	13	465	404	142	92	84	45	613
Ruqin Chen United States	11	511 1.1×	559 1.4×	161 1.1×	88 1.0×	42 0.5×	22	764
Ryo Ko Japan	12	299 0.6×	392 1.0×	122 0.9×	87 0.9×	31 0.4×	60	547
Anna Manzo Italy	10	248 0.5×	170 0.4×	164 1.2×	73 0.8×	82 1.0×	25	398
Ivana Sullivan Spain	14	509 1.1×	322 0.8×	218 1.5×	100 1.1×	81 1.0×	55	686
Luckson Mathieu United States	8	290 0.6×	254 0.6×	157 1.1×	75 0.8×	55 0.7×	12	526
Sung Jin Yoon South Korea	10	613 1.3×	733 1.8×	233 1.6×	134 1.5×	44 0.5×	18	904
Priscilla Cascetta Italy	10	234 0.5×	135 0.3×	142 1.0×	84 0.9×	57 0.7×	15	368
A. Sandler United States	16	524 1.1×	390 1.0×	120 0.8×	80 0.9×	98 1.2×	35	604
Qiong Zhao China	14	299 0.6×	196 0.5×	145 1.0×	82 0.9×	30 0.4×	28	503
Giuseppe Colantuoni Italy	13	317 0.7×	182 0.5×	185 1.3×	86 0.9×	36 0.4×	28	509

Countries citing papers authored by Sakiko Otani

Since Specialization

Citations

This map shows the geographic impact of Sakiko Otani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sakiko Otani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sakiko Otani more than expected).

Fields of papers citing papers by Sakiko Otani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sakiko Otani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sakiko Otani. The network helps show where Sakiko Otani may publish in the future.

Co-authorship network of co-authors of Sakiko Otani

This figure shows the co-authorship network connecting the top 25 collaborators of Sakiko Otani. A scholar is included among the top collaborators of Sakiko Otani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sakiko Otani. Sakiko Otani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nakahara, Yoshiro, Hideaki Manabe, Sakiko Otani, et al.. (2022). Promising Response to Dabrafenib Plus Trametinib in a Patient with Peritoneal Carcinomatosis from Non Small Lung Cancer Harboring BRAF V600E Mutation. OncoTargets and Therapy. Volume 15. 1369–1374. 4 indexed citations

Ikeda, Satoshi, Terufumi Kato, Takashi Ogura, et al.. (2018). Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016. BMC Cancer. 18(1). 241–241. 9 indexed citations

Shirasawa, Masayuki, Tomoya Fukui, Yasuhiro Hiyoshi, et al.. (2018). Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer. Cancer Management and Research. Volume 10. 6039–6047. 18 indexed citations

Otani, Sakiko, et al.. (2018). Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report. Respiratory Medicine Case Reports. 23. 131–135.

Igawa, Satoshi, Masaaki Ichinoe, Sakiko Otani, et al.. (2017). Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations. Oncology Research and Treatment. 40(1-2). 7–13. 8 indexed citations

Kasajima, Masashi, Satoshi Igawa, Sakiko Otani, et al.. (2017). Correlation between the efficacy of amrubicin and the previous chemotherapy regimen for relapsed small cell lung cancer. Oncology Letters. 13(3). 1719–1724. 4 indexed citations

Nakahara, Yoshiro, Jiichiro Sasaki, Tomoya Fukui, et al.. (2017). The role of prophylactic cranial irradiation for patients with small-cell lung cancer. Japanese Journal of Clinical Oncology. 48(1). 26–30. 12 indexed citations

Igawa, Satoshi, Sakiko Otani, Yoshiro Nakahara, et al.. (2017). Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non–small cell lung cancer. Investigational New Drugs. 36(1). 45–52. 3 indexed citations

Fukui, Tomoya, Yoshiro Nakahara, Sakiko Otani, et al.. (2017). A prospective observational study of immune checkpoint inhibitor nivolumab treatment in patients with non-small cell lung cancer. Annals of Oncology. 28. x135–x135. 1 indexed citations

10.

Okamoto, Hiroaki, Jiichiro Sasaki, Noriyuki Masuda, et al.. (2017). Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604. BMC Cancer. 17(1). 377–377. 8 indexed citations

11.

Igawa, Satoshi, Sakiko Otani, Shinichiro Ryuge, et al.. (2017). Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer. Investigational New Drugs. 35(5). 642–648. 4 indexed citations

12.

Igawa, Satoshi, Yuichi Sato, Shinichiro Ryuge, et al.. (2017). Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer. Oncology. 92(5). 283–290. 34 indexed citations

13.

Otani, Sakiko, Jiichiro Sasaki, Kazuya Okamoto, et al.. (2016). Abstract 2284: Synergistic anti-tumor effect of the combination of amrubicin and erlotinib in non-small cell lung cancer with wild type EGFR. Cancer Research. 76(14_Supplement). 2284–2284.

14.

Igawa, Satoshi, Nobuyuki Yanagisawa, Yasuhiro Hiyoshi, et al.. (2015). Successful chemotherapy with carboplatin and nab-paclitaxel for thymic large cell neuroendocrine carcinoma: A case report. Oncology Letters. 10(6). 3519–3522. 8 indexed citations

15.

Igawa, Satoshi, Keigo Gohda, Tomoya Fukui, et al.. (2014). Circulating tumor cells as a prognostic factor in patients with small cell lung cancer. Oncology Letters. 7(5). 1469–1473. 56 indexed citations

16.

Igawa, Satoshi, S. Maki, Sakiko Otani, et al.. (2014). Successful Chemotherapy with Nab-Paclitaxel in a Heavily Treated Non-Small Cell Lung Cancer Patient: A Case Report. Case Reports in Oncology. 7(2). 401–406. 3 indexed citations

17.

Igawa, Satoshi, Jiichiro Sasaki, Sakiko Otani, et al.. (2013). Evaluation of Amrubicin as a Third or Later Line of Chemotherapy for Advanced Non-Small Cell Lung Cancer. Chemotherapy. 59(2). 99–105. 5 indexed citations

18.

Doi, Toshihiko, Nozomu Fuse, Takayuki Yoshino, et al.. (2011). Phase I study of AMG 479, a fully human monoclonal antibody against the type 1 insulin-like growth factor receptor (IGF-1R), in Japanese patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 29(4_suppl). 318–318. 2 indexed citations

19.

Igawa, Satoshi, Shinichiro Ryuge, Tomoya Fukui, et al.. (2010). Amrubicin for treating elderly and poor-risk patients with small-cell lung cancer. International Journal of Clinical Oncology. 15(5). 447–452. 13 indexed citations

20.

Fukui, Tomoya, Sakiko Otani, Ryuji Hataishi, et al.. (2009). Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. Cancer Chemotherapy and Pharmacology. 65(4). 803–806. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact